Reauthorizes a sickle cell disease prevention and treatment demonstration program and expresses the sense of Congress that further research is needed.
The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 amends the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program. It updates the program's focus to include the treatment of sickle cell disease and the prevention and treatment of its complications. The bill also expresses the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.